Investing
Cathie Wood's ARK Invest Sells Over 225,000 Shares of Takeda Pharma

Published:
Last Updated:
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Tuesday, as the share price of this fund traded down over 2% in the day’s session. The fund’s share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 228,234 shares of Takeda Pharma. At Tuesday’s closing price, this would have valued this sale at roughly $3.9 million. This is only a small fraction of the total holdings. This fund is up 88% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
Fund | Ticker | Company | Shares |
---|---|---|---|
ARKF | TCSLI | TCS GROUP HOLDING PLC | 50,650 |
ARKG | PSTI | PLURISTEM THERAPEUTICS INC | 1,131 |
ARKG | NVS | NOVARTIS AG | 139,576 |
ARKG | SRPT | SAREPTA THERAPEUTICS INC | 48,004 |
ARKG | TAK | TAKEDA PHARMACEUTICAL CO LTD | 228,234 |
ARKK | ICE | INTERCONTINENTAL EXCHANGE INC | 196,304 |
ARKQ | TER | TERADYNE INC | 23,160 |
ARKQ | RAVN | RAVEN INDUSTRIES INC | 32,733 |
ARKQ | GLEO | GALILEO ACQUISITION CORP | 5,888 |
ARKW | NET | CLOUDFLARE INC | 72,257 |
ARKX | AIRFP | AIRBUS SE | 16,050 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: am I ahead, or behind on my goals?
Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With Zoe Financial’s free matching tool, you can connect with trusted financial advisors in minutes.
Why wait? Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.